Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design

• Main Authors: Sushant B. Jadhav (Author), Rahul M. Mane (Author), Kalyanraman L. Narayanan (Author), Popatrao N. Bhosale (Author)
• Format: Book
• Published: MDPI AG, 2016-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2218-0532; 10.3390/scipharm84040671
• Keywords: S-isomer; enantiomer; design of experiments (DoE); development; linagliptin and metformin hydrochloride; Pharmacy and materia medica; RS1-441
• Source: Scientia Pharmaceutica, Vol 84, Iss 4, Pp 671-684 (2016)

A novel, stability indicating, reverse phase high-performance liquid chromatography (RP-HPLC) method was developed to determine the S-isomer of linagliptin (LGP) in linagliptin and metformin hydrochloride (MET HCl) tablets (LGP-MET HCl) by implementing design of experiment (DoE), i.e., two-level, full factorial design (23 + 3 centre points = 11 experiments) to understand the critical method parameters (CMP) and its relation with the critical method attribute (CMA), and to ensure robustness of the method. The separation of the S-isomer, LGP and MET HCl in the presence of their impurities was achieved on Chiralpak® IA-3 (Amylose tris (3, 5-dimethylphenylcarbamate), immobilized on 3 µm silica gel) stationary phase (250 × 4.6 mm, 3 µm) using isocratic elution and detector wavelength at 225 nm with a flow rate of 0.5 mL·min−1, an injection volume of 10 µL with a sample cooler (5 °C) and column oven temperature of 25 °C. Ethanol:Methanol:Monoethanolamine (EtOH:MeOH:MEA) in the ratio of 60:40:0.2 v/v/v was used as a mobile phase. The developed method was validated in accordance with international council for harmonisation (ICH) guidelines and was applied for the estimation of the S-isomer of LGP in LGP-MET HCl tablets. The same method also can be extended for the estimation of the S-isomer in LGP dosage forms.